Struggling long-term Lumos holders see hope as biotech stock inks A$1.1M order

The thing about biotech is that when a stock gets key approvals and smashes its third-phase-trial goals, it can tend to make overnight millionaires. Of course, like all high-risk-high-reward ventures, the opposite can be true.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

Then there are healthcare junior companies in between: biotech stocks that don’t necessarily miss out on licences or third-phase goalposts but who, licensed to go out into the healthcare market, just don’t quite satisfy the heady expectations punters had convinced themselves would be flowing into their wallets.

LDX, for the uninformed, ultimately produces a fingerstick blood sample test that can differentiate between bacterial and non-bacterial origins of respiratory infections.

Lumos Diagnostics (ASX:LDX), a former ASX and HotCopper forums darling, is one of those companies. Through the back half of last year, the stock climbed from under 10cps to 32cps at the start of 2026. Not quite the meteoric gains of which legends are made, but still exciting for anybody who had put in a decent amount to begin with.

And the rise of LDX should be seen in its appropriate context alongside 4DX Medical – a $2B market cap company that basically doesn’t make any money yet – but whose tickers were similar enough that many people talked of holding both LDX and 4DX if for nothing more than the sake of portfolio harmony.

That 30c valuation faltered in CYQ126, came back to the fore in March of this year, but since then – and coinciding with the US war in Iran more than anything, which put the entire ASX risk-off – Lumos has been struggling. Geopol macro wasn’t enough to see a key FDA approval in March of this year mean much at all, to the chagrin of investors.

Which means anybody who bought at 30cps – this finance journalist is aware that’s a common enough occurrence across multiple online investment communities – has probably been kicking themselves the last few months.

Enter good news on Tuesday of this week. The company has today unveiled an A$1.09M order (US$760K) from an entity called PHASE Scientific for its fingerstick blood test product.

“This purchase order is the initial order associated with the US$5.0 million prepayment milestone received by Lumos following the grant of CLIA waiver for FebriDx by the U.S. FDA on 27 March 2026,” Lumos elaborated on Tuesday.

“The order satisfies part of the Year 1 minimum order quantity commitment under the distribution agreement with PHASE Scientific and will be credited against the prepayment, with the remaining prepayment balance available to support subsequent purchase orders.”

Products will be delivered to PHASE into October of 2026, and LDX shares on Tuesday jumped nearly +20% on the back of some A$315K worth of trades.

But anybody who bought at 30cps is probably now waiting for the next contract deal to drop – as fickle as biotech investors generally tend to be, with the massive uncertainty still hovering over global markets through H2CY26, calm nerves are unlikely to permeate without a lion’s conviction, or chemical assistance.

Join the discussion: See what’s trending right now on HotCopper, Australia’s largest stock forum, and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.